The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease

Orazio Schillaci, Mariangela Pierantozzi, Luca Filippi, Carlo Manni, Livia Brusa, Roberta Danieli, Giorgio Bernardi, Giovanni Simonetti, Paolo Stanzione

Research output: Contribution to journalArticle

Abstract

Purpose: The aim of this study was to evaluate, by means of 123I-FP-CIT SPECT, the effect of chronic treatment with levodopa on striatal dopamine transporter (DAT) in patients with Parkinson's disease. Methods: Fifteen patients under stable levodopa/carbidopa monotherapy were imaged twice: at baseline on medication and after at least 20 days of treatment wash-out. DAT levels were assessed from SPECT imaging for the entire striatum, the right and left striatum, the right and left putamen and the right and left caudate, as a ratio of regional brain activities using the formula: (striatal region of interest-occipital)/occipital. Results: During levodopa wash-out, despite a worsening in patients' clinical disability (H&Y mean stage 2.53±0.58 versus 1.73±0.45 on therapy, p123I-FP-CIT levels were not significantly different from those at baseline in any of the brain regions examined. Conclusion: The results of this study suggest that levodopa does not affect 123I-FP-CIT brain imaging and confirm that it is not necessary to withdraw this medication to measure DAT levels with SPECT.

Original languageEnglish
Pages (from-to)1452-1456
Number of pages5
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume32
Issue number12
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Levodopa
Single-Photon Emission-Computed Tomography
Parkinson Disease
Corpus Striatum
Occipital Lobe
Putamen
Brain
Neuroimaging
Therapeutics
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane

Keywords

  • I-FP-CIT
  • Dopamine transporter
  • Levodopa
  • Parkinson's disease
  • SPECT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease. / Schillaci, Orazio; Pierantozzi, Mariangela; Filippi, Luca; Manni, Carlo; Brusa, Livia; Danieli, Roberta; Bernardi, Giorgio; Simonetti, Giovanni; Stanzione, Paolo.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 32, No. 12, 12.2005, p. 1452-1456.

Research output: Contribution to journalArticle

Schillaci, O, Pierantozzi, M, Filippi, L, Manni, C, Brusa, L, Danieli, R, Bernardi, G, Simonetti, G & Stanzione, P 2005, 'The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease', European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 12, pp. 1452-1456. https://doi.org/10.1007/s00259-005-1922-9
Schillaci, Orazio ; Pierantozzi, Mariangela ; Filippi, Luca ; Manni, Carlo ; Brusa, Livia ; Danieli, Roberta ; Bernardi, Giorgio ; Simonetti, Giovanni ; Stanzione, Paolo. / The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease. In: European Journal of Nuclear Medicine and Molecular Imaging. 2005 ; Vol. 32, No. 12. pp. 1452-1456.
@article{9634d14f80a44fc497054fdddd44dee9,
title = "The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease",
abstract = "Purpose: The aim of this study was to evaluate, by means of 123I-FP-CIT SPECT, the effect of chronic treatment with levodopa on striatal dopamine transporter (DAT) in patients with Parkinson's disease. Methods: Fifteen patients under stable levodopa/carbidopa monotherapy were imaged twice: at baseline on medication and after at least 20 days of treatment wash-out. DAT levels were assessed from SPECT imaging for the entire striatum, the right and left striatum, the right and left putamen and the right and left caudate, as a ratio of regional brain activities using the formula: (striatal region of interest-occipital)/occipital. Results: During levodopa wash-out, despite a worsening in patients' clinical disability (H&Y mean stage 2.53±0.58 versus 1.73±0.45 on therapy, p123I-FP-CIT levels were not significantly different from those at baseline in any of the brain regions examined. Conclusion: The results of this study suggest that levodopa does not affect 123I-FP-CIT brain imaging and confirm that it is not necessary to withdraw this medication to measure DAT levels with SPECT.",
keywords = "I-FP-CIT, Dopamine transporter, Levodopa, Parkinson's disease, SPECT",
author = "Orazio Schillaci and Mariangela Pierantozzi and Luca Filippi and Carlo Manni and Livia Brusa and Roberta Danieli and Giorgio Bernardi and Giovanni Simonetti and Paolo Stanzione",
year = "2005",
month = "12",
doi = "10.1007/s00259-005-1922-9",
language = "English",
volume = "32",
pages = "1452--1456",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "12",

}

TY - JOUR

T1 - The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease

AU - Schillaci, Orazio

AU - Pierantozzi, Mariangela

AU - Filippi, Luca

AU - Manni, Carlo

AU - Brusa, Livia

AU - Danieli, Roberta

AU - Bernardi, Giorgio

AU - Simonetti, Giovanni

AU - Stanzione, Paolo

PY - 2005/12

Y1 - 2005/12

N2 - Purpose: The aim of this study was to evaluate, by means of 123I-FP-CIT SPECT, the effect of chronic treatment with levodopa on striatal dopamine transporter (DAT) in patients with Parkinson's disease. Methods: Fifteen patients under stable levodopa/carbidopa monotherapy were imaged twice: at baseline on medication and after at least 20 days of treatment wash-out. DAT levels were assessed from SPECT imaging for the entire striatum, the right and left striatum, the right and left putamen and the right and left caudate, as a ratio of regional brain activities using the formula: (striatal region of interest-occipital)/occipital. Results: During levodopa wash-out, despite a worsening in patients' clinical disability (H&Y mean stage 2.53±0.58 versus 1.73±0.45 on therapy, p123I-FP-CIT levels were not significantly different from those at baseline in any of the brain regions examined. Conclusion: The results of this study suggest that levodopa does not affect 123I-FP-CIT brain imaging and confirm that it is not necessary to withdraw this medication to measure DAT levels with SPECT.

AB - Purpose: The aim of this study was to evaluate, by means of 123I-FP-CIT SPECT, the effect of chronic treatment with levodopa on striatal dopamine transporter (DAT) in patients with Parkinson's disease. Methods: Fifteen patients under stable levodopa/carbidopa monotherapy were imaged twice: at baseline on medication and after at least 20 days of treatment wash-out. DAT levels were assessed from SPECT imaging for the entire striatum, the right and left striatum, the right and left putamen and the right and left caudate, as a ratio of regional brain activities using the formula: (striatal region of interest-occipital)/occipital. Results: During levodopa wash-out, despite a worsening in patients' clinical disability (H&Y mean stage 2.53±0.58 versus 1.73±0.45 on therapy, p123I-FP-CIT levels were not significantly different from those at baseline in any of the brain regions examined. Conclusion: The results of this study suggest that levodopa does not affect 123I-FP-CIT brain imaging and confirm that it is not necessary to withdraw this medication to measure DAT levels with SPECT.

KW - I-FP-CIT

KW - Dopamine transporter

KW - Levodopa

KW - Parkinson's disease

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=28544444147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28544444147&partnerID=8YFLogxK

U2 - 10.1007/s00259-005-1922-9

DO - 10.1007/s00259-005-1922-9

M3 - Article

C2 - 16151764

AN - SCOPUS:28544444147

VL - 32

SP - 1452

EP - 1456

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 12

ER -